These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31743263)

  • 1. Sustained Response to Pegloticase Without Infusion Reactions Despite Multiple Lapses in Treatment in Patient With Severe Tophaceous Gout.
    Schmidt JN; Cunningham MA
    J Clin Rheumatol; 2021 Dec; 27(8S):S491-S494. PubMed ID: 31743263
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 3. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Bessen SY; Bessen MY; Yung CM
    Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 8. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal arthritis. Intensive urate-lowering therapy improves structural joint damage in patients with tophaceous gout.
    Buckland J
    Nat Rev Rheumatol; 2013 Sep; 9(9):506. PubMed ID: 23897441
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
    Schlesinger N; Lipsky PE
    Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic perspectives on uricases for gout.
    Garay RP; El-Gewely MR; Labaune JP; Richette P
    Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase for treatment of tophaceous polyarticular gout.
    Seifried RM; Roberts J
    Hawaii J Med Public Health; 2013 Jul; 72(7):220-3. PubMed ID: 23901393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Johnson RJ; Choi HK; Yeo AE; Lipsky PE
    Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
    Freyne B
    Transplant Proc; 2018 Dec; 50(10):4099-4101. PubMed ID: 30577324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series.
    Botson JK; Peterson J
    J Clin Rheumatol; 2022 Jan; 28(1):e129-e134. PubMed ID: 33044389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
    Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.